![Inge Lues](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Inge Lues worked as Vice President-Global Drug Discovery at Merck KGaA in 2007.
From 2008 to 2018, Lues worked at Vivoryon Therapeutics NV, where she held the position of Chief Development Officer from 2013 to 2018.
Eerdere bekende functies van Inge Lues
| Bedrijven | Functie | Einde |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Hoofd Techniek/Wetenschap/O&O | 31-10-2018 |
| MERCK KGAA | Corporate Officer/Principal | 01-01-2007 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
11
Eerstegraads connecties
2
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Vivoryon Therapeutics NV
 Vivoryon Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that is engaged in the research and development of new therapeutic products for the treatment of Alzheimer disease | Commercial Services |
